MeiraGTx Holdings, which is developing gene therapies for disorders of the eye and salivary gland, raised $75 million by offering 5 million shares at $15, the midpoint of the $14 to $16 range. At pricing, the company will command a fully diluted market value of $423 million and an enterprise value of $302 million. MeiraGTx Holdings plans to list on the Nasdaq under the symbol MGTX. BofA Merrill Lynch, Barclays and Evercore ISI acted as lead managers on the deal.
